Mahon et al. recently demonstrated that nilotinib-resistant CML cell lines were able to upregulate the expression of BCR-ABL, thus overcoming the inhibitory threshold of nilotinib [105]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.